Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...

This brief explores what access to care, coordination of care, and quality of care look like for older adults with health ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

COVID, flu and RSV levels have already hit their peaks. (Pollen levels and springtime allergies are a whole different story.) ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...